Terms: = Lung cancer AND CCDC6, D10S170, 8030, ENSG00000108091, Q16204, TPC, H4, TST1 AND Treatment
117 results:
1. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC.
Liu JS; Cai YX; He YZ; Xu J; Tian SF; Li ZQ
BMC Cancer; 2024 Jan; 24(1):123. PubMed ID: 38267913
[TBL] [Abstract] [Full Text] [Related]
2. Discovery of 4-((3,4-dichlorophenyl)amino)-2-methylquinolin-6-ol derivatives as EGFR and HDAC dual inhibitors.
Qian Y; Zhou S; Li J; Ma M; Chen H; Cao Y; Zhang Y; Sun C; Li K; Liu Y; Dai S; Ao M; Fang M; Wu Z; Li M
Eur J Pharmacol; 2023 Dec; 960():176114. PubMed ID: 37863412
[TBL] [Abstract] [Full Text] [Related]
3. Discovery, validation, and prodrug design of an ACE2 activator for treating bacterial infection-induced lung inflammation.
Lu P; Leslie F; Wang H; Sodhi A; Choi CY; Pekosz A; Cui H; Jia H
J Control Release; 2023 Dec; 364():1-11. PubMed ID: 37858626
[TBL] [Abstract] [Full Text] [Related]
4. Intracranial Activity of Selpercatinib in Chinese Patients With Advanced
Cheng Y; Huang D; Zhou J; Zhou C; Sun Y; Wu L; Guo Y; Jingxin S; Zhang W; Lu S
JCO Precis Oncol; 2023 Jun; 7():e2200708. PubMed ID: 37315261
[TBL] [Abstract] [Full Text] [Related]
5. Establishment and visualization of a model based on high-resolution CT qualitative and quantitative features for prediction of micropapillary or solid components in invasive lung adenocarcinoma.
Dong H; Wang X; Qiu Y; Lou C; Ye Y; Feng H; Ye X; Chen D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10519-10530. PubMed ID: 37289235
[TBL] [Abstract] [Full Text] [Related]
6. OHCCPredictor: an online risk stratification model for predicting survival duration of older patients with hepatocellular carcinoma.
Tan J; Yu Y; Lin X; He Y; Jin W; Qian H; Li Y; Xu X; Zhao Y; Ning J; Zhang Z; Chen J; Wu X
Hepatol Int; 2024 Apr; 18(2):550-567. PubMed ID: 37067674
[TBL] [Abstract] [Full Text] [Related]
7. Osimertinib and Selpercatinib Efficacy, Safety, and Resistance in a Multicenter, Prospectively Treated Cohort of EGFR-Mutant and RET Fusion-Positive lung cancers.
Rotow J; Patel JD; Hanley MP; Yu H; Awad M; Goldman JW; Nechushtan H; Scheffler M; Kuo CS; Rajappa S; Harada G; Clifford S; Santucci A; Silva L; Tupper R; Oxnard GR; Kherani J; Drilon A
Clin Cancer Res; 2023 Aug; 29(16):2979-2987. PubMed ID: 36996322
[TBL] [Abstract] [Full Text] [Related]
8. Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell lung cancer Patients Treated with Immune Checkpoint Inhibitors.
Genova C; Tasso R; Rosa A; Rossi G; Reverberi D; Fontana V; Marconi S; Croce M; Dal Bello MG; Dellepiane C; Tagliamento M; Ciferri MC; Zullo L; Fedeli A; Alama A; Cortese K; Gentili C; Cella E; Anselmi G; Mora M; Barletta G; Rijavec E; Grossi F; Pronzato P; Coco S
Cells; 2023 Mar; 12(6):. PubMed ID: 36980174
[TBL] [Abstract] [Full Text] [Related]
9. Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network.
Li S; Li W; Ma T; Fu S; Gao X; Qin N; Wu Y; Zhang X; Wang J; Pan Y; Liu Z
Front Immunol; 2022; 13():1024707. PubMed ID: 36518765
[TBL] [Abstract] [Full Text] [Related]
10. Durable response to low-dose pralsetinib in a renal insufficient patient with NSCLC harboring concurrent ccdc6-RET, LINCO1264-RET, and SEMA5A-RET fusions: A case report.
Gu L; Ji W; Xu Y; Han Y; Jian H
Medicine (Baltimore); 2022 Nov; 101(47):e31480. PubMed ID: 36451418
[TBL] [Abstract] [Full Text] [Related]
11. Histomolecular Resistance Mechanisms to First-Line Osimertinib in EGFR-Mutated Advanced Non-Small Cell lung cancer: A Multicentric Retrospective French Study.
Akli A; Girard N; Fallet V; Rousseau-Bussac G; Gounant V; Friard S; Trédaniel J; Dujon C; Wislez M; Duchemann B; Giroux-Leprieur E
Target Oncol; 2022 Nov; 17(6):675-682. PubMed ID: 36129569
[TBL] [Abstract] [Full Text] [Related]
12. An integrative pan cancer analysis of RET aberrations and their potential clinical implications.
Zhou L; Li J; Zhang X; Xu Z; Yan Y; Hu K
Sci Rep; 2022 Aug; 12(1):13913. PubMed ID: 35978072
[TBL] [Abstract] [Full Text] [Related]
13. Pan-cancer efficacy of pralsetinib in patients with RET fusion-positive solid tumors from the phase 1/2 ARROW trial.
Subbiah V; Cassier PA; Siena S; Garralda E; Paz-Ares L; Garrido P; Nadal E; Vuky J; Lopes G; Kalemkerian GP; Bowles DW; Seetharam M; Chang J; Zhang H; Green J; Zalutskaya A; Schuler M; Fan Y; Curigliano G
Nat Med; 2022 Aug; 28(8):1640-1645. PubMed ID: 35962206
[TBL] [Abstract] [Full Text] [Related]
14. Pralsetinib treatment for multiple
Cao X; Liu X; Wang S; Liu Z; Ren X; Sun D; Deng L
J Int Med Res; 2022 Jun; 50(6):3000605221105368. PubMed ID: 35751411
[TBL] [Abstract] [Full Text] [Related]
15. Inhibition of FGF receptor blocks adaptive resistance to RET inhibition in ccdc6-RET-rearranged thyroid cancer.
Raman R; Villefranc JA; Ullmann TM; Thiesmeyer J; Anelli V; Yao J; Hurley JR; Pauli C; Bareja R; Wha Eng K; Dorsaint P; Wilkes DC; Beg S; Kudman S; Shaw R; Churchill M; Ahmed A; Keefer L; Misner I; Nichol D; Gumpeni N; Scognamiglio T; Rubin MA; Grandori C; Solomon JP; Song W; Mosquera JM; Dephoure N; Sboner A; Elemento O; Houvras Y
J Exp Med; 2022 Jun; 219(6):. PubMed ID: 35510953
[TBL] [Abstract] [Full Text] [Related]
16. Loss of KMT5C Promotes EGFR Inhibitor Resistance in NSCLC via LINC01510-Mediated Upregulation of MET.
Pal AS; Agredo A; Lanman NA; Son J; Sohal IS; Bains M; Li C; Clingerman J; Gates K; Kasinski AL
Cancer Res; 2022 Apr; 82(8):1534-1547. PubMed ID: 35404406
[TBL] [Abstract] [Full Text] [Related]
17. B7-H4 expression promotes non-small cell lung cancer progression via AMPK/mTOR signaling.
Li M; Che N; Feng Y; Liu X; Piao L; Xuan Y; Jin Y
Exp Mol Pathol; 2022 Apr; 125():104755. PubMed ID: 35278461
[TBL] [Abstract] [Full Text] [Related]
18. Discovery of N-Trisubstituted Pyrimidine Derivatives as Type I RET and RET Gatekeeper Mutant Inhibitors with a Novel Kinase Binding Pose.
Zhang L; Moccia M; Briggs DC; Bharate JB; Lakkaniga NR; Knowles P; Yan W; Tran P; Kharbanda A; Wang X; Leung YK; Frett B; Santoro M; McDonald NQ; Carlomagno F; Li HY
J Med Chem; 2022 Jan; 65(2):1536-1551. PubMed ID: 35081714
[TBL] [Abstract] [Full Text] [Related]
19. Landscape and Clonal Dominance of Co-occurring Genomic Alterations in Non-Small-Cell lung cancer Harboring
Le X; Hong L; Hensel C; Chen R; Kemp H; Coleman N; Ciunci CA; Liu SV; Negrao MV; Yen J; Xia X; Scheuenpflug J; Stroh C; Juraeva D; Tsao A; Hong D; Raymond V; Paik P; Zhang J; Heymach JV
JCO Precis Oncol; 2021; 5():. PubMed ID: 34957368
[TBL] [Abstract] [Full Text] [Related]
20. Pralsetinib: treatment of metastatic RET fusion-positive non-small cell lung cancer.
Nguyen L; Monestime S
Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
[TBL] [Abstract] [Full Text] [Related]
[Next]
